Market Overview

Independent Study Shows Effectiveness of Covidien's Blood Clot Prevention Technology

Covidien
(NYSE: COV), a leading global provider of healthcare products, today
announced that an independent study conducted by the University of
Edinburgh has successfully demonstrated the effectiveness of Covidien's
Kendall SCD™ system with Vascular Refill Detection Technology on
immobile stroke patients.

An independent study conducted by the University of Edinburgh has successfully demonstrated the effectiveness of Covidien's Kendall SCD(TM) system with Vascular Refill Detection Technology on immobile stroke patients. (Photo: Business Wire)

The results of the CLOTS 3 trial were presented at the European
Stroke Conference by Professor Martin S. Dennis of the University of
Edinburgh's Division of Clinical Neurosciences and also published in The
Lancet. The new study showed a 29.9% decrease in the development

See full press release

Posted-In: News Guidance Contracts Management Global

 

Most Popular

Related Articles (COV)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional